{
  "slug": "eggshell-membrane",
  "name": "Eggshell Membrane (NEM)",
  "alternate_names": [
    "Natural Eggshell Membrane (NEM)",
    "NEM",
    "Membrana de cáscara de huevo",
    "Eggshell membrane hydrolysate"
  ],
  "mechanism": [
    "Type I/V/X collagen substrate supply to connective tissue",
    "Glycosaminoglycan (chondroitin sulfate) and hyaluronic acid contribution to joint matrix",
    "Down-regulation of pro-inflammatory cytokines IL-1beta and TNF-alpha (in-vitro / mechanistic)",
    "Modulation of cartilage-turnover biomarkers (CTX-II) in research settings"
  ],
  "target": [
    "Articular cartilage extracellular matrix (type I/V/X collagen)",
    "Hyaluronic acid",
    "Chondroitin sulfate / glycosaminoglycans",
    "Pro-inflammatory cytokines (IL-1beta, TNF-alpha)",
    "Cartilage-turnover biomarker CTX-II"
  ],
  "use_case": [
    "joint flexibility and comfort (research context)",
    "post-exercise joint recovery and range of motion (research context)",
    "connective tissue metabolic support (research context)",
    "joint stiffness markers (research context)"
  ],
  "body_system": [
    "MUSCULO",
    "CONNECTIVE"
  ],
  "evidence_tier": "A",
  "evidence_anchor_pmid_count": 4,
  "dosage_range": "500 mg/day Natural Eggshell Membrane (NEM); the only dose validated in controlled trials. Onset of pain/stiffness change observed within 7-10 days in RCTs; typical intervention 1-8 weeks.",
  "safety_notes": "Generally well tolerated at 500 mg/day in published RCTs; rare gastrointestinal discomfort reported. CONTRAINDICATED in individuals with egg allergy — eggshell membrane is egg-derived and must carry an egg-allergen declaration. Safety of NEM supported by García-Muñoz 2024 meta-analysis (PMID 39203777). Pregnancy/lactation data limited.",
  "regulatory": {
    "fda": "US: DSHEA-legal dietary-supplement ingredient; NEM (Natural Eggshell Membrane) holds FDA GRAS status (self-affirmed GRAS (ESM Technologies NEM; a recent FDA GRAS notice also filed)). Structure/function claims permitted; no FDA authorized health claim.",
    "efsa": "EU: no EFSA authorized health claim under Reg 432/2012; may require Novel Food safety assessment at EU level (some member states have products on market; no harmonized EU authorization).",
    "anvisa": "BR: no specific ANVISA approval; requires new-ingredient pathway evaluation under the suplemento alimentar framework (RDC 243/2018); market access uncertain. (CN: non-traditional food ingredient under NMPA — new-food-ingredient or health-food registration required; access pathway unclear.)"
  },
  "authorized_claims": [],
  "ingredient_hub_url": "https://asxan.ai/ingredients/eggshell-membrane/",
  "related_goal_slugs": [
    "joint-bone"
  ],
  "related_lifestyle_slugs": [
    "senior-60-plus"
  ],
  "last_evidence_review": "2026-06-13",
  "schema_version": "nc-public-v0.2",
  "api_version": "nc-public-v0.3",
  "_meta": {
    "last_evidence_review": "2026-06-13",
    "ip_axes_disclosed": {
      "public_axes": [
        "mechanism",
        "target",
        "use_case",
        "body_system",
        "evidence_tier",
        "dosage_range",
        "safety_notes",
        "regulatory",
        "authorized_claims"
      ],
      "ip_axes_not_exposed": [
        "proprietary_formula_ratios",
        "clinical_protocol_internals",
        "rnd_pipeline_compounds",
        "supplier_specific_grade_specifications",
        "unpublished_endpoint_data"
      ],
      "rationale": "asxan.ai surfaces the educational, evidence-tier-disclosed slice. Formula composition, clinical-protocol internals, and RnD pipeline data are intentionally outside this public surface."
    }
  }
}